[Seven Innovent Biologics products are included in the new version of the National Reimbursement Catalog, covering four major fields including oncology and metabolism] The reporter learned that a total of 7 Innovent Biologics products (including first inclusion, new indications and renewals) have been successfully included in the 2026 new version of the National Reimbursement Catalog released today. Among them, the products included in the medical insurance for the first time include the GCG/GLP-1 dual receptor agonist Xinermei® (Masdutide injection), IL-23p19 inhibitor Xinmeiyue® (piconibizumab injection), etc.; new indications have been expanded. The products on display include the PD-1 inhibitor Tyvyt® (sintilimab injection) and the BTK small molecule inhibitor Jepali® (pitubrutinib tablets); the cardiovascular metabolism product Symbio® (tolesimab injection) has successfully renewed its contract. Currently, 17 of the company's 20 marketed products have been included in the national medical insurance catalog, covering the four major fields of oncology, metabolism, autoimmunity and ophthalmology. (Reporter Yu Miao)